RIGEL PHARMACEUTICALS INC — Earnings
Most recent reported period: FY2026 (Q1) (filed for period ending 2026-03-31) · sourced from SEC EDGAR
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2026-03-31 | $59M | ↑+10.3% | $9M | ↓-24.4% | 20.2% |
| 2025-12-31 | $70M | ↑+21.2% | $268M | ↑+5193.5% | 33.2% |
| 2025-09-30 | $69M | ↑+25.6% | $28M | ↑+124.6% | 40.9% |
| 2025-06-30 | $102M | ↑+176.0% | $60M | ↑+5887.7% | 60.1% |
| 2025-03-31 | $53M | ↑+80.6% | $11M | ↑+238.8% | 23.9% |
| 2024-12-31 | $58M | ↑+60.9% | $5M | ↑+587.1% | 17.6% |
| 2024-09-30 | $55M | ↑+96.6% | $12M | ↑+318.2% | 25.4% |
| 2024-06-30 | $37M | ↑+37.0% | $-1M | ↑+84.4% | 1.2% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2026 (Q1)
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 64 quarters
margin trajectory tells the operating-leverage storyGo deeper
RIGL Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyRIGL Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics